dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Majem Tarruella, Margarita |
dc.contributor.author | García‑Martínez, E. |
dc.contributor.author | Martinez, M. |
dc.contributor.author | Rodriguez‑Abreu, D. |
dc.contributor.author | Alvarez, R. |
dc.contributor.author | Muñoz Couselo, Eva |
dc.date.accessioned | 2021-09-15T07:39:25Z |
dc.date.available | 2021-09-15T07:39:25Z |
dc.date.issued | 2020-02 |
dc.identifier.citation | Majem M, García-Martínez E, Martinez M, Muñoz-Couselo E, Rodriguez-Abreu D, Alvarez R, et al. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clin Transl Oncol. 2020 Feb;22:213–222. |
dc.identifier.issn | 1699-3055 |
dc.identifier.uri | https://hdl.handle.net/11351/6313 |
dc.description | Inmunoterapia; Toxicidad; irAEs |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical and Translational Oncology;22 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Immunoteràpia - Efectes secundaris |
dc.subject | Càncer - Tractament |
dc.subject | Protocols clínics |
dc.subject.mesh | Immunotherapy |
dc.subject.mesh | /adverse effects |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Practice Guidelines as Topic |
dc.title | SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12094-019-02273-x |
dc.subject.decs | inmunoterapia |
dc.subject.decs | /efectos adversos |
dc.subject.decs | neoplasias |
dc.subject.decs | guías de práctica clínica como asunto |
dc.relation.publishversion | https://doi.org/10.1007/s12094-019-02273-x |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Majem M] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [García-Martínez E] Department of Medical Oncology and Hematology, Hospital Universitario Morales Meseguer, Murcia, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Martinez M] Department of Medical Oncology, Hospital del Mar, Barcelona, Spain. [Muñoz-Couselo E] Servei de Medicina Oncològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Melanoma and Other Skin Tumors Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rodriguez-Abreu D] Department of Medical Oncology, C.H.U. Insular-Materno Infantil de Gran Canaria, Las Palmas, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Alvarez R] Department of Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain |
dc.identifier.pmid | 31993963 |
dc.identifier.wos | 000514525700006 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |